Shopping Cart 0
Cart Subtotal
USD 0

Multiple Sclerosis Drugs Market Global Report 2020-30

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 4000

Access to Printed Report; No Soft Copy
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 6000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

CD-Rom
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8000

Details

The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.
 
The global multiple sclerosis drugs market was worth USD 20.83 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 5.20% and reach USD 25.52 billion by 2023.
 
The multiple sclerosis drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America is expected to be the largest region in the forecast period.
 
The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others. It is also segmented by distribution channels into hospital pharmacy, retail pharmacy, and online stores and by route of administration: oral drugs and, parenteral drugs.
 
The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested USD 1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of USD 10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market.
 
The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. As reported by Institute for Clinical and Economic Review (ICER) in 2017, the MS drugs costs roughly between USD 63,000 and USD 104,000 annually. For instance, in 2019, after receiving criticism by National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to USD 88,000 per year in order to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.
 
The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.
 
In 2019, Bristol-Myers Squibb, a USA based pharmaceutical company, acquired Celgene for USD 74billion. Through the acquisition Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of the Celgene's pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis.
 
Major players in the market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.
READ MORE

Table Of Content

Scope

1. Executive Summary

2. Multiple Sclerosis Drugs Market Characteristics

3. Multiple Sclerosis Drugs Market Size And Growth

3.1. Global Multiple Sclerosis Drugs Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Multiple Sclerosis Drugs Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Multiple Sclerosis Drugs Market Segmentation

4.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Immunomodulators

Immunosuppressants

Interferons

Others

4.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Hospital Pharmacy

Retail Pharmacy

Online Stores

4.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Oral drugs

Parenteral drugs

5. Multiple Sclerosis Drugs Market Regional And Country Analysis

5.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Multiple Sclerosis Drugs Market

6.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview

6.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Multiple Sclerosis Drugs Market

7.1. China Multiple Sclerosis Drugs Market Overview

7.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

7.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Multiple Sclerosis Drugs Market

8.1. India Multiple Sclerosis Drugs Market Overview

8.2. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

8.3. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Multiple Sclerosis Drugs Market

9.1. Japan Multiple Sclerosis Drugs Market Overview

9.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Multiple Sclerosis Drugs Market

10.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Multiple Sclerosis Drugs Market

11.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Multiple Sclerosis Drugs Market

12.1. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Multiple Sclerosis Drugs Market

13.1. Western Europe Multiple Sclerosis Drugs Market Overview

13.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Multiple Sclerosis Drugs Market

14.1. UK Multiple Sclerosis Drugs Market Overview

14.2. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14.3. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Multiple Sclerosis Drugs Market

15.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Multiple Sclerosis Drugs Market

16.4. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16.5. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Multiple Sclerosis Drugs Market

17.1. Eastern Europe Multiple Sclerosis Drugs Market Overview

17.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Multiple Sclerosis Drugs Market

18.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Multiple Sclerosis Drugs Market

19.1. North America Multiple Sclerosis Drugs Market Overview

19.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Multiple Sclerosis Drugs Market

20.1. USA Multiple Sclerosis Drugs Market Overview

20.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Multiple Sclerosis Drugs Market

21.1. South America Multiple Sclerosis Drugs Market Overview

21.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Multiple Sclerosis Drugs Market

22.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Multiple Sclerosis Drugs Market

23.1. Middle East Multiple Sclerosis Drugs Market Overview

23.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Multiple Sclerosis Drugs Market

24.1. Africa Multiple Sclerosis Drugs Market Overview

24.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

25.1. Multiple Sclerosis Drugs Market Competitive Landscape

25.2. Multiple Sclerosis Drugs Market Company Profiles

25.2.1. Biogen

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Novartis

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. Roche

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Bayer HealthCare

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. Pfizer, Inc.

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

27. Multiple Sclerosis Drugs Market Trends And Strategies

28. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List Of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 46: Biogen Financial Performance

Figure 47: Novartis Financial Performance

Figure 48: Roche Financial Performance

Figure 49: Bayer HealthCare Financial Performance

Figure 50: Pfizer, Inc. Financial Performance


List Of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 46: Biogen Financial Performance

Table 47: Novartis Financial Performance

Table 48: Roche Financial Performance

Table 49: Bayer HealthCare Financial Performance

Table 50: Pfizer, Inc. Financial Performance

Licence Rights

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others; 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores; 3) By Route Of Administration: Oral Drugs; Parenteral Drugs


Companies

Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.; Merck & Co., Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline; Acorda Therapeutics Inc.; Actelion Pharmaceuticals (Johnson & Johnson); EMD Serono (Merck KGaA); AbbVie, Inc.; Betaseron; CinnoVex; Extavia; Rebif; Tysabr

Company Profile

Company Profile Title

The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.
 
The global multiple sclerosis drugs market was worth USD 20.83 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 5.20% and reach USD 25.52 billion by 2023.
 
The multiple sclerosis drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America is expected to be the largest region in the forecast period.
 
The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others. It is also segmented by distribution channels into hospital pharmacy, retail pharmacy, and online stores and by route of administration: oral drugs and, parenteral drugs.
 
The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested USD 1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of USD 10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market.
 
The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. As reported by Institute for Clinical and Economic Review (ICER) in 2017, the MS drugs costs roughly between USD 63,000 and USD 104,000 annually. For instance, in 2019, after receiving criticism by National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to USD 88,000 per year in order to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.
 
The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.
 
In 2019, Bristol-Myers Squibb, a USA based pharmaceutical company, acquired Celgene for USD 74billion. Through the acquisition Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of the Celgene's pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis.
 
Major players in the market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.
READ MORE

Scope

1. Executive Summary

2. Multiple Sclerosis Drugs Market Characteristics

3. Multiple Sclerosis Drugs Market Size And Growth

3.1. Global Multiple Sclerosis Drugs Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Multiple Sclerosis Drugs Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Multiple Sclerosis Drugs Market Segmentation

4.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Immunomodulators

Immunosuppressants

Interferons

Others

4.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Hospital Pharmacy

Retail Pharmacy

Online Stores

4.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Oral drugs

Parenteral drugs

5. Multiple Sclerosis Drugs Market Regional And Country Analysis

5.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Multiple Sclerosis Drugs Market

6.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview

6.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Multiple Sclerosis Drugs Market

7.1. China Multiple Sclerosis Drugs Market Overview

7.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

7.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Multiple Sclerosis Drugs Market

8.1. India Multiple Sclerosis Drugs Market Overview

8.2. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

8.3. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Multiple Sclerosis Drugs Market

9.1. Japan Multiple Sclerosis Drugs Market Overview

9.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Multiple Sclerosis Drugs Market

10.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Multiple Sclerosis Drugs Market

11.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Multiple Sclerosis Drugs Market

12.1. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Multiple Sclerosis Drugs Market

13.1. Western Europe Multiple Sclerosis Drugs Market Overview

13.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Multiple Sclerosis Drugs Market

14.1. UK Multiple Sclerosis Drugs Market Overview

14.2. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14.3. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Multiple Sclerosis Drugs Market

15.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Multiple Sclerosis Drugs Market

16.4. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16.5. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Multiple Sclerosis Drugs Market

17.1. Eastern Europe Multiple Sclerosis Drugs Market Overview

17.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Multiple Sclerosis Drugs Market

18.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Multiple Sclerosis Drugs Market

19.1. North America Multiple Sclerosis Drugs Market Overview

19.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Multiple Sclerosis Drugs Market

20.1. USA Multiple Sclerosis Drugs Market Overview

20.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Multiple Sclerosis Drugs Market

21.1. South America Multiple Sclerosis Drugs Market Overview

21.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Multiple Sclerosis Drugs Market

22.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Multiple Sclerosis Drugs Market

23.1. Middle East Multiple Sclerosis Drugs Market Overview

23.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Multiple Sclerosis Drugs Market

24.1. Africa Multiple Sclerosis Drugs Market Overview

24.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

25.1. Multiple Sclerosis Drugs Market Competitive Landscape

25.2. Multiple Sclerosis Drugs Market Company Profiles

25.2.1. Biogen

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Novartis

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. Roche

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Bayer HealthCare

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. Pfizer, Inc.

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

27. Multiple Sclerosis Drugs Market Trends And Strategies

28. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List Of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 46: Biogen Financial Performance

Figure 47: Novartis Financial Performance

Figure 48: Roche Financial Performance

Figure 49: Bayer HealthCare Financial Performance

Figure 50: Pfizer, Inc. Financial Performance


List Of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 46: Biogen Financial Performance

Table 47: Novartis Financial Performance

Table 48: Roche Financial Performance

Table 49: Bayer HealthCare Financial Performance

Table 50: Pfizer, Inc. Financial Performance

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others; 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores; 3) By Route Of Administration: Oral Drugs; Parenteral Drugs


Companies

Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.; Merck & Co., Inc.; Sanofi; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline; Acorda Therapeutics Inc.; Actelion Pharmaceuticals (Johnson & Johnson); EMD Serono (Merck KGaA); AbbVie, Inc.; Betaseron; CinnoVex; Extavia; Rebif; Tysabr